News & Views
Beximico Pharma Extends Reach into Gulf Market
Jul 08 2016
Beximco Pharmaceuticals Limited, a fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, has commenced the export of pharmaceuticals to Kuwait. This marks the first time a Bangladeshi pharmaceutical company has launched pharmaceutical products in any Gulf member country under the Gulf Cooperation Council (GCC).
A ceremony held at the company’s Beximco Pharma factory in Dhaka in the presence of the Ambassador of Kuwait, His Excellency Mr. Adel Mohammad A. H Hayat, celebrated the launch of the initial shipment, which included two metered-dose inhaler products for asthma and other respiratory conditions, along with a blood pressure drug.
Managing Director of Beximco Pharma, Nazmul Hassan MP, commented:
“Beximco Pharma continues to build its presence in emerging and developed markets. The Company is increasingly focused on regulated markets, such as the US, EU, GCC and Australia, where the demand for generic pharmaceutical products is rising. The Gulf market is an important market for us and the launch of our products in Kuwait will open up new opportunities in the region. We will continue to expand our product range in the Gulf market, providing patients with safe and affordable treatment options.”
Beximco Pharma said to be the largest exporter of pharmaceuticals in Bangladesh, has won the country’s National Export Trophy a record five times. It has a global footprint in more than 50 countries and has been accredited by a number of global regulatory authorities, including the US FDA, AGES (EU), TGA Australia, Health Canada, GCC and TFDA.
Digital Edition
MAC Guide 2023/24
December 2023
Buyers Guide - Major producers of analytical equipment who wish to introduce and sell their products to buyers in science and industry - Over 1,000 products and services that these companys man...
View all digital editions
Events
Jan 17 2024 Birmingham, UK
Jan 24 2024 Tokyo, Japan
Jan 29 2024 Dubai, UAE
Jan 31 2024 Tokyo, Japan
Feb 03 2024 Boston, MA, USA